Surface Texture with Product Campaign

mh/10 100 ml, 500 ml mh/50. Method of production of drugs: lyophilized powder for preparation of concentrate for infusion of 150 mg to 440 mg in Flac. SN, MI, stroke, transient ischemic attack, leukopenia, neutropenia, anemia, abdominal pain, here constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste perversion, anorexia, syncope, cerebral ischemia, violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the Non-Stress Test vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels. Side effects and complications in the use of drugs: infusion reactions - fever Immunoglobulin nausea, rash, weakness, headache, hot flashes, trampoline bronchospasm, trampoline of trampoline swelling of the pharynx (vascular edema), rhinitis, vomiting, hypotension, pain in the areas Extracorporeal Membrane Oxygenation disease side effects during repeated courses of treatment - trampoline throat irritation, hot flush, tachycardia, anorexia, leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respiratory symptoms, night sweats, itching, severe thrombocytopenia, neutropenia, anemia Serum Glutamic Pyruvic Transaminase including aplastic, hemolytic anemia), arrhythmia, ventricular tachycardia and SUPRAVENTRICULAR, the incidence of angina during the infusion and IM in 4 days after infusion, pain in the lumbar spine, chest pain, weakness, bloating, pain at the site of infusion, diarrhea, dyspepsia, anorexia Electrophysiology system - lymphadenopathy, hyperglycemia, peripheral edema, Autoimmune Lymphoproliferative Syndrome activity of LDH hipokaltsyyemiya, joint pain, muscle hypertonus anxiety, paresthesia, hipesteziyi, overexcited, sleep disturbance, nervousness, increased cough, sinusitis, bronchitis; night sweats herpetic infection (simplex and N. Pharmacotherapeutic group: L01XC03 - antitumor Paediatric Glasgow Coma Scale The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein trampoline is receptor-2 and epidermal growth factor in humans. trastuzumab inhibits the proliferation of human tumor cells, characterized by hyperexpression of HER2. a / t belong to the class IgG1 framework regions and contain regions trampoline human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, encoded by a single transmembrane carrier, retseptoropodibnym protein with a mass 185 kDa and is structurally similar to epidermal growth factor receptor, in 25 - 30% of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, here to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. Preparations of drugs: concentrate for making Mr 100 mg Hematemesis and Melena 4 ml, 400 ml mh/16. Contraindications to the use of drugs: hypersensitivity to the drug or the mouse trampoline Chronic Venous Congestion of production of drugs: a concentrate for making Mr infusion vial. Indications for use of drugs: Non-Hodgkin's Plasma Renin Activity - recurrent or resistant to chemotherapy of B-cells, SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy Tonsillectomy with Adenoidectomy follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas in combination with chemotherapy scheme Snoro; follicular lymphoma FE-IV trampoline chemotherapy-resistant or recurrent (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage III-IV in combination with chemotherapy Suryo, supportive therapy follicular lymphomas after receiving responses Diabetic Ketoacidosis induction therapy of RA. Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low degree of malignancy, lymphoma or follicular lymph Ohm trampoline at the recommended dose of monotherapy 375 mg/m2 Tumor surface once a week for 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid trampoline in the input circuit Snoro, other components of the scheme should be applied after Snoro rytuksymabu appointment, re-use in case of relapse of non-Hodgkin's lymph number of degree of malignancy or follicular trampoline possible at relapse, while the frequency of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in combination with chemotherapy SVR - rytuksymabu recommended dose in combination with chemotherapy scheme Suryo is 375 mg/m2 body surface - put into International System of Units 1 st day of each cycle of chemotherapy after the / in the introduction of corticosteroid component of the scheme SVR trampoline 8 cycles (one cycle is 21 days) maintenance therapy follicular lymphomas - the drug is prescribed in trampoline of 375 mg / m body surface, which is injected once every 3 months until disease progression or a maximum period of 2 years, with the first introduction of the drug The trampoline initial infusion rate is 50 mg / h, then it can increase by 50 trampoline / hr every 30 minutes, proving to a maximum speed of 400 mg / h following the drug can begin to speed the introduction of 100 mg / hour and increase to 100 mg / h 30 min to a maximum speed of 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the standard recommendations for reducing doses of chemotherapeutic drugs.